Stryker Corporation $SYK Shares Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its position in Stryker Corporation (NYSE:SYK) by 25.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,745 shares of the medical technology company’s stock after buying an additional 6,683 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Stryker were worth $9,018,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its position in shares of Stryker by 1.2% during the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after acquiring an additional 183,400 shares in the last quarter. Wellington Management Group LLP increased its stake in Stryker by 0.6% in the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares during the last quarter. Bank of America Corp DE acquired a new position in Stryker during the second quarter valued at approximately $1,404,284,000. Royal Bank of Canada raised its position in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Stryker by 21.8% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after purchasing an additional 481,175 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on SYK shares. Stifel Nicolaus reduced their target price on Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. TD Cowen lowered their price target on Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Canaccord Genuity Group dropped their price objective on Stryker from $400.00 to $385.00 and set a “buy” rating for the company in a research report on Friday, September 18th. Finally, Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Stryker Price Performance

Shares of SYK stock opened at $301.59 on Wednesday. The business’s 50-day moving average price is $294.70 and its 200-day moving average price is $325.45. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts predict that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.